Fibrin Or Derivative Affecting Or Utilizing Patents (Class 514/13.6)
-
Patent number: 8603982Abstract: A medical composition is described in which a synthetic polymer substrate and a composition mainly composed of a biopolymer directly adhere to each other due to dissolution of the surfaces thereof. The medical composition allows one to attach a biopolymer composition to a synthetic polymer substrate without the use of a toxic adhesive.Type: GrantFiled: March 30, 2009Date of Patent: December 10, 2013Assignee: FUJIFILM CorporationInventors: Shouji Ooya, Kentaro Nakamura
-
Publication number: 20130324469Abstract: Methods for diagnosing and monitoring acute kidney injury (AKI) based on urinary fibrinogen levels, and methods for treating AKI using a Bbeta15-42 peptide.Type: ApplicationFiled: December 7, 2011Publication date: December 5, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Vishal S. Vaidya
-
Patent number: 8575101Abstract: Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, which are used to heal bone fractures, particularly bone fractures with a risk of becoming delayed unions or non-unions, are described herein. The PTH is incorporated either through covalent linkage to the matrix or through non-covalent interaction with the matrix and/or the granules. These supplemented matrices decrease the time of healing compared to autograft and or trigger healing of bone fractures which otherwise would not heal. The matrices are biocompatible, preferably biodegradable, and can be formed in vitro or in vivo, at the time of implantation. The PTH may be a part of a fusion peptide. PTH can be incorporated into the matrices with full retention of its bioactivity. PTH can be releasably incorporated in the matrix.Type: GrantFiled: June 23, 2011Date of Patent: November 5, 2013Assignee: Kuros Biosurgery AGInventors: Jason Schense, John Watson, Isabelle Arrighi
-
Publication number: 20130280321Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.Type: ApplicationFiled: June 18, 2013Publication date: October 24, 2013Inventors: Curtis E. Olson, Philip A. Messina
-
Patent number: 8563510Abstract: Methods and apparatus for a free-standing biodegradable patch suitable for medical applications, especially intravascular, minimally-invasive and intraoperative surgical applications are provided, wherein the patch comprises a free-standing film or device having a mixture of a solid fibrinogen component and a solid thrombin component that, when exposed to an aqueous environment, undergoes polymerization to form fibrin. In alternative embodiments the patch may comprise a solid fibrinogen component, with or without an inorganic calcium salt component. The patch may take a non-adherent form during delivery to a target location within a vessel or tissue, and thereafter may be activated to adhere to vessel wall or tissue, and may include a number of additives, including materials to improve the mechanical properties of the patch, or one or more therapeutic or contrast agents.Type: GrantFiled: September 17, 2010Date of Patent: October 22, 2013Assignee: Bioinspire Technologies, Inc.Inventors: Dorna Hakimimehr, Raoul Bonan
-
Patent number: 8557773Abstract: The invention provides low-half life fibrinogen with reduced sialyation as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.Type: GrantFiled: April 29, 2009Date of Patent: October 15, 2013Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Publication number: 20130267466Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.Type: ApplicationFiled: February 20, 2013Publication date: October 10, 2013Inventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Publication number: 20130267467Abstract: The invention provides methods of making and using compounds of the formula shown, which are inhibitors of human plasmin and plasma kallikrein. (Formula I) The compounds are useful for the prevention of blood loss, and as components of fibrin adhesives.Type: ApplicationFiled: July 5, 2011Publication date: October 10, 2013Inventors: Torsten Steinmetzer, Sebastian Martin Saupe
-
Publication number: 20130245528Abstract: Provided herein is a topical wound dressing that comprises a collagen and a flexible paste. Also provided is a wound dressing with a first layer of a sterilized mixture of collagen and a second adhesive layer effective to adhere to surrounding skin and to keep the first layer in contact with the wound. In addition there is provided a wound dressing foil that comprises collagen and a plastic compound that can provide a foil shape. Furthermore, methods of dressing wounds utilizing the wound dressings and wound dressing foil are provided herein.Type: ApplicationFiled: March 13, 2013Publication date: September 19, 2013Inventor: Carl Randall Harrell
-
Patent number: 8529959Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529958Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529961Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529960Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carnell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529956Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: April 17, 2008Date of Patent: September 10, 2013Assignees: Carnell Therapeutics Corporation, Carnegie Mellon University, Allegheny-Singer Research InstituteInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8513380Abstract: Compositions and methods for targeting substances to fibrinogen, fibrin monomers, or fibrin polymers are provided. These compositions and methods generally involve the use of fibrin knob peptides that bind fibrin(ogen), which can be used to detect fibrin(ogen) and modulate fibrin polymerization and fibrinolysis.Type: GrantFiled: July 9, 2010Date of Patent: August 20, 2013Assignee: Georgia Tech Research CorporationInventor: Thomas Harrison Barker
-
Patent number: 8512740Abstract: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, will rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing. A fibrin foam may be made by injecting fibrinogen foam into a clotting protein, such as thrombin.Type: GrantFiled: March 26, 2008Date of Patent: August 20, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventor: Yves A. Delmotte
-
Publication number: 20130202674Abstract: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment.Type: ApplicationFiled: October 4, 2012Publication date: August 8, 2013Applicant: Dynasil Biomedical CorporationInventor: Daniel Grant Ericson
-
Publication number: 20130202675Abstract: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment.Type: ApplicationFiled: October 4, 2012Publication date: August 8, 2013Applicant: Dynasil Biomedical CorporationInventor: Dynasil Biomedical Corporation
-
Publication number: 20130202656Abstract: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment.Type: ApplicationFiled: October 4, 2012Publication date: August 8, 2013Applicant: Dynasil Biomedical CorporationInventor: Dynasil Biomedical Corporation
-
Patent number: 8501693Abstract: The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.Type: GrantFiled: August 6, 2007Date of Patent: August 6, 2013Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Dennis Kim, Michael Trautmann
-
Patent number: 8476010Abstract: A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.Type: GrantFiled: July 10, 2003Date of Patent: July 2, 2013Assignee: APP Pharmaceuticals LLCInventors: Neil P. Desai, Andrew Yang, Sherry Xiaopei Ci
-
Patent number: 8466107Abstract: Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging, etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.Type: GrantFiled: August 30, 2012Date of Patent: June 18, 2013Assignee: Bracco Imaging SpAInventors: Philippe Bussat, Bernard Lamy, Edmund R. Marinelli, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Patent number: 8454980Abstract: Hydrogel compositions that include an albumin/N-acetyl cysteine solution and an aqueous suspension of calcium salts or mixture of calcium and magnesium salts are described. Also described are methods of producing and using the hydrogel compositions as a support scaffold for mineralizing connective tissue replacement and repair.Type: GrantFiled: January 26, 2012Date of Patent: June 4, 2013Inventor: Stanley William Whitson
-
Patent number: 8440618Abstract: The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in a short period of time after implantation. The invention also relates to the use and manufacture of this novel composition, as well as a novel use for the protein CNA.Type: GrantFiled: January 19, 2012Date of Patent: May 14, 2013Assignees: New York Society for the Ruptured and Crippled Maintaining the Hospital for Special Surgery, The Trustees of Princeton University, The Texas A&M University SystemInventors: Suzanne A. Maher, Jeffrey Schwartz, Axel Oscar Magnus Hook, Brooke Hageman Russell, Casey Marie Jones
-
Publication number: 20130095165Abstract: A hemostatic product that includes a dextran support, at least one hemostatic agent and at least one hemostatic agent stabilizer. The at least one hemostatic agent is selected from the group consisting of thrombin and fibrinogen. The at least one hemostatic agent is associated with the dextran support. The at least one hemostatic agent stabilizer is associated with the at least one hemostatic agent.Type: ApplicationFiled: September 19, 2012Publication date: April 18, 2013Applicant: ST. TERESA MEDICAL, INC.Inventor: St. Teresa Medical, Inc.
-
Publication number: 20130084278Abstract: The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.Type: ApplicationFiled: November 26, 2012Publication date: April 4, 2013Applicant: Hepacore Ltd.Inventor: Hepacore Ltd.
-
Publication number: 20130064864Abstract: A submicron protein sphere and method to intravenously treat a patient requiring blood component transfusion. The submicron protein spheres have a size ranging from 1.0 micron to less than 0.1 micron and a molecular weight ranging from 780 billion Daltons to less than 0.8 billion Daltons. The protein spheres have no biologically active molecules added or bound to the protein spheres prior to administering to the patient. The protein used to construct the spheres can be human serum albumin from natural sources or recombinant DNA-derived serum albumin, or other proteins such as gelatin or synthetic polypeptides. However, the protein spheres can bind the various clotting factors including fibrinogen after the spheres have entered the blood stream, binding the necessary additional biologically active molecules supplied in vivo from the patient's own blood, and possibly in vitro.Type: ApplicationFiled: September 6, 2012Publication date: March 14, 2013Inventor: Richard C.K. Yen
-
Publication number: 20130058880Abstract: Compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses are disclosed. The compositions or kits contain polyvinyl acetal (PVA), siloxane and a solvent. The siloxane can have a hydrophilic group. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and siloxane is solidified, forming a film. The compositions and kits, optionally, further include one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent. Such a film can be used, for example, in the form of an antimicrobial sealant, a liquid bandage, body paints, scar camouflage, water-proof sun block, makeup sealer, or antimicrobial wipe or spray.Type: ApplicationFiled: May 9, 2011Publication date: March 7, 2013Inventor: Shaosheng Dong
-
Patent number: 8383147Abstract: The present invention is directed to a reinforced absorbable hemostat comprising at least one hemostatic agent in a single layer of nonwoven synthetic fabric having a mixture of compressed fiber staples of a polyglycolide/polylactide copolymer and a polydioxanone.Type: GrantFiled: August 22, 2012Date of Patent: February 26, 2013Assignee: Ethicon, Inc.Inventors: Dhanuraj S. Shetty, Olajompo Moloye-Olabisi, Robert W. Van Holten, Degang Zhong
-
Publication number: 20130029913Abstract: Therapeutic agents suitable for use as artificial platelets are described. The agents comprise a fibrinogen binding precursor bound to an insoluble carrier, wherein the fibrinogen binding precursor can be converted by a wound site specific agent, such as thrombin, to a fibrinogen binding component bound to the carrier. The fibrinogen binding component has increased ability to bind fibrinogen compared to the fibrinogen binding precursor. The agents may be used to treat patients with deficiencies in their own platelets, such as hereditary or acquired defects of platelet numbers (thrombocytopenia) or function (thrombasthenia).Type: ApplicationFiled: February 29, 2012Publication date: January 31, 2013Inventors: Alison Helena Goodall, Sarah Margaret Taylor, Greg Francis Walker
-
Publication number: 20130011382Abstract: The present invention relates to fibrinogen preparations enriched in ?-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of ?-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by ?-extended fibrinogen are improved. In addition, plasmin-mediated degradation of ?-extended fibrinogen is reduced as compared to plasma derived fibrinogen.Type: ApplicationFiled: January 7, 2011Publication date: January 10, 2013Applicant: PROFIBRIX BVInventors: Joseph Grimbergen, Jacob Koopman, Abraham Bout
-
Publication number: 20130004478Abstract: The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.Type: ApplicationFiled: June 30, 2011Publication date: January 3, 2013Inventors: Yi-Lan Wang, Guanghui Zhang
-
Publication number: 20120328512Abstract: Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging, etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.Type: ApplicationFiled: August 30, 2012Publication date: December 27, 2012Applicant: BRACCO IMAGING S.P.A.Inventors: Philippe Bussat, Bernard Lamy, Edmund R. Marinelli, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Patent number: 8329211Abstract: The present invention is directed to a synthetic fabric comprising a multi-layered nonwoven fabric made from staples of a polyglycolide/polylactide copolymer, each layer having a different density. The multi-layer fabric can be used as a reinforced absorbable hemostat medical device.Type: GrantFiled: May 17, 2010Date of Patent: December 11, 2012Assignee: Ethicon, Inc.Inventors: Olajompo Moloye-Olabisi, Dhanuraj S. Shetty, Robert W. Van Holten, Degang Zhong
-
Publication number: 20120308658Abstract: The described invention provides a nonhuman animal model system for hemorrhagic brain conditions, methods for evaluating a substance for treating the hemorrhagic brain condition in a mammal, methods for treating hematoma expansion or recurrent rebleeding resulting from hemorrhagic brain conditions in a mammal, and pharmaceutical compositions for administration into or at a distance proximal to the hemorrhagic brain condition.Type: ApplicationFiled: July 13, 2012Publication date: December 6, 2012Inventor: R. Loch Macdonald
-
Patent number: 8318661Abstract: The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and spontaneous otitis media in an animal model.Type: GrantFiled: August 28, 2007Date of Patent: November 27, 2012Assignee: Omnio Healer ABInventors: Tor Ny, Jinan Li, Yongzhi Guo
-
Publication number: 20120289467Abstract: A composition including a peptide sequence of the formula ?X1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type ?15-42 monomer sequence per se, and wherein the peptide sequence is other than (?15-66)2 dimer having two chains with each chain limited to wild type amino acids ?15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4.Type: ApplicationFiled: September 17, 2008Publication date: November 15, 2012Applicant: University of Maryland, BaltimoreInventors: Leonid Medved, Li Zhang, Sergiy Yakovlev
-
Publication number: 20120288564Abstract: There is provided a method of forming a hydrogel, the method comprising: providing a mixture of a polymer comprising a cross-linkable pendant phenolic group, peroxidase, H2O2, fibrinogen, and thrombin, at concentration sufficient to enzymatically cross-link the polymer and to cleave the fibrinogen to yield fibrin; and allowing the mixture to form a hydrogel. There is also provided a hydrogel comprising a cross-linked network of a polymer interpenetrated by fibrin fibers, the polymer cross-linked by oxidative coupling between phenolic groups pendant on the polymer.Type: ApplicationFiled: May 11, 2011Publication date: November 15, 2012Inventors: Motoichi Kurisawa, Fan Lee
-
Patent number: 8309518Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF? superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.Type: GrantFiled: July 28, 2010Date of Patent: November 13, 2012Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jason C. Schense, Hugo Schmoekel, Jeffrey A. Hubbell, Franz Weber
-
Publication number: 20120282235Abstract: Embodiments of the present invention include a surgical kit for preparation of a patch for implantation into a human body, characterized in that it comprises a package containing, on one hand, a synthetic substrate (1) and, on the other hand, means for treatment of the substrate with a solution (3) including at least one biologically active component (4, 5), adapted to integrate the biologically active component with the substrate. Embodiments of the invention include a patch for implantation into the human body, comprising a synthetic substrate (1), characterized in that at least one biologically active component (4, 5) is integrated with the substrate using the surgical kit.Type: ApplicationFiled: June 1, 2010Publication date: November 8, 2012Inventors: Kevin L. Ohashi, Dale R. Peterson, Jamal Rushdy
-
Publication number: 20120253298Abstract: A tissue thickness compensator may generally comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a third layer comprising a third medicament. The tissue thickness compensator may comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a reservoir comprising a third medicament disposed within the reservoir. The medicaments may be independently selected from a haemostatic agent, an anti-inflammatory agent, an antibiotic agent, anti-microbial agent, an anti-adhesion agent, an anti-coagulant agent, a pharmaceutically active agent, a matrix metalloproteinase inhibitor, and combinations thereof. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.Type: ApplicationFiled: March 28, 2012Publication date: October 4, 2012Applicant: Ethicon Endo-Surgery, Inc.Inventors: Cortney E. Henderson, Taylor W. Aronhalt, Chunlin Yang, Charles J. Scheib, Venkataramanan Mandakolathur Vasudevan, Mark D. Timmer, Richard W. Timm, Tamara Widenhouse, Steven G. Hall
-
Patent number: 8278274Abstract: Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging, etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.Type: GrantFiled: December 11, 2007Date of Patent: October 2, 2012Assignee: Bracco Imaging SpAInventors: Philippe Bussat, Bernard Lamy, Edmund R. Marinelli, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Patent number: 8273369Abstract: The present invention is directed to a reinforced absorbable hemostat comprising at least one hemostatic agent in a single layer of nonwoven synthetic fabric having a mixture of compressed fiber staples of a polyglycolide/polylactide copolymer and a polydioxanone.Type: GrantFiled: May 17, 2010Date of Patent: September 25, 2012Assignee: Ethicon, Inc.Inventors: Olajompo Moloye-Olabisi, Dhanuraj S. Shetty, Robert W. Van Holten, Degang Zhong
-
Publication number: 20120219534Abstract: Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.Type: ApplicationFiled: May 7, 2012Publication date: August 30, 2012Applicant: PROCHON BIOTECH LTD.Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Publication number: 20120208758Abstract: The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in a short period of time after implantation. The invention also relates to the use and manufacture of this novel composition, as well as a novel use for the protein CNA.Type: ApplicationFiled: January 19, 2012Publication date: August 16, 2012Applicant: NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERYInventors: Suzanne A. Maher, Jeffrey Schwartz, Axel Oscar Magnus Hook, Brooke Hageman Russell, Casey Marie Jones
-
Publication number: 20120195883Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: ApplicationFiled: April 17, 2012Publication date: August 2, 2012Applicant: VENTRIA BIOSCIENCEInventors: NING HUANG, RAYMOND L. RODRIQUEZ, FRANK E. HAGIE, DAVID M. STALKER
-
Publication number: 20120189668Abstract: Hydrogel compositions that include an albumin/N-acetyl cysteine solution and an aqueous suspension of calcium salts or mixture of calcium and magnesium salts are described. Also described are methods of producing and using the hydrogel compositions as a support scaffold for mineralizing connective tissue replacement and repair.Type: ApplicationFiled: January 26, 2012Publication date: July 26, 2012Inventor: Stanley William Whitson
-
Publication number: 20120177610Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.Type: ApplicationFiled: May 24, 2011Publication date: July 12, 2012Inventor: Kieu Hoang
-
Publication number: 20120156284Abstract: The invention includes a composition useful for preparing a tissue sealant for use on a patient, comprising: autologous fibrinogen, an activating agent and at least one supplement. The invention includes a method of treating a disc having at least one defect, comprising: introducing a composition into the disc, wherein the composition comprises autologous fibrinogen and an activating agent, and wherein the composition forms fibrin.Type: ApplicationFiled: February 28, 2012Publication date: June 21, 2012Inventors: Brian D. Burkinshaw, Steven I. Whitlock, James B. Rogan, Gerald L. Devries
-
Publication number: 20120121572Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.Type: ApplicationFiled: May 14, 2010Publication date: May 17, 2012Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Matteo D'Este, Giovanni Gennari